Dyspnoea management in acute coronary syndrome patients treated with ticagrelor

The occurrence of dyspnoea in acute coronary syndrome (ACS) patients has always been considered a challenging diagnostic and therapeutic clinical scenario. P2Y12 platelet receptor inhibitors (i.e., clopidogrel, prasugrel and ticagrelor) are currently the cornerstone of treatment of ACS patients. Thus, in the last few years, the potential association between ACS and dyspnoea has also become more challenging with the increasing use of ticagrelor in these patients due to its beneficial effects on ischaemic event prevention and mortality, since ticagrelor can induce dyspnoea as a side effect. The present article is intended to review the current literature regarding dyspnoea occurrence in ACS patients, especially those treated with ticagrelor, and to propose ticagrelor-associated dyspnoea management recommendations based on current knowledge.

• Publication year

  2015

• Venue

  European heart journal. Acute cardiovascular care

• Publication date

  2015-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/2048872614554108PMID 25267878PMCID 4657388
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Are there Symptom Differences in Patients with Coronary Artery Disease Presenting to the Emergency Department Ultimately Diagnosed with or without Acute Coronary Syndrome ?

  2016cited by this paper
• Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).

  2014cited by this paper
• A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease: Results of the SWAP-2 Study

  2013cited by this paper
• Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial.

  2013cited by this paper
• Switching from prasugrel to clopidogrel: navigating in unknown waters.

  2013cited by this paper
• Switching acute coronary syndrome patients from prasugrel to clopidogrel.

  2013cited by this paper
• ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

  2012cited by this paper
• ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.

  2012cited by this paper
• Are there symptom differences in patients with coronary artery disease presenting to the ED ultimately diagnosed with or without ACS?

  2012cited by this paper
• Welcome to the European Heart Journal: Acute Cardiovascular Care

  2012cited by this paper
• Why does ticagrelor induce dyspnea?

  2012cited by this paper
• 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

  2011cited by this paper
• High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.

  2011cited by this paper
• Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.

  2011cited by this paper
• Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).

  2011cited by this paper
• Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study

  2010cited by this paper
• Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.

  2010cited by this paper
• The impact of dyspnea on health-related quality of life in patients with coronary artery disease: results from the PREMIER registry.

  2009influential reference
• Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect.

  2008cited by this paper
• Acute heart failure in patients with acute myocardial infarction treated with primary percutaneous coronary intervention ☆

  2008cited by this paper
• Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.

  2007cited by this paper
• Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.

  2006cited by this paper
• Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes.

  2006cited by this paper
• Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events.

  2004cited by this paper

• Ticagrelor-Associated Central Sleep Apnea: A Case Report and Review of the Literature

  2025cites this paper
• Effectiveness and Safety of Ticagrelor Monotherapy After Short-Duration Dual Antiplatelet Therapy in PCI Patients: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Aspirin and Ticagrelor Versus Aspirin and Clopidogrel or Pasugrel and the Effect on Staphylococcal-Associated Infections: A Real-world Study.

  2024cites this paper
• Discharge of Acute Coronary Syndrome Patients on Sub-Optimal Dual Anti-Platelet Therapy: A Single Center Experience

  2024cites this paper
• A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor

  2024cites this paper
• Ticagrelor-Related Dyspnea Beyond Adenosine: Insights into Retrotrapezoid Hyperactivity.

  2024cites this paper
• Assessment of Quality of Life in Patients Under Go Neangioplasty and Takin Gticagrelor: A Prospective   Observational Study

  2024cites this paper
• The Impact of FEV1/FVC Ratio on the Clinical Outcomes in Acute Coronary Syndrome Patients Treated with Dual Anti-Platelet Agents.

  2023cites this paper
• Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study.

  2023cites this paper
• Clinical Impact of Dyspnea after Ticagrelor Treatment and the Effect of Switching to Clopidogrel in Patients with Myocardial Infarction

  2023cites this paper
• Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention.

  2023cites this paper
• Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients: Rationale and Design of the LEGACY study.

  2023cites this paper
• The effects of P2Y12 adenosine receptors’ inhibitors on central and peripheral chemoreflexes

  2023cites this paper
• Pathophysiological and Molecular Basis of the Side Effects of Ticagrelor: Lessons from a Case Report

  2023cites this paper
• Effect of altitude on ticagrelor-induced dyspnea in patients with acute coronary syndrome

  2023cites this paper
• Ticagrelor use in patients after percutaneous coronary intervention: one year follow up in a community hospital.

  2022cites this paper
• Several Non-salt and Solid Thienopyridine Derivatives as Oral P2Y12 Receptor Inhibitors with Good Stability.

  2022cites this paper
• P2Y12-inhibitor monotherapy after coronary stenting: are all P2Y12-inhibitors equal?

  2022cites this paper
• Current views on antiplatelet therapy in acute coronary syndrome patients: the place of clopidogrel

  2022cites this paper
• Temporal Trends of Bleeding Episodes during Half- vs. Standard-Dose Ticagrelor in Acute Coronary Syndrome Patients with Low Platelet Reactivity: A Randomized BLEEDING-ACS Trial

  2021cites this paper
• Long term dual antiplatelet therapy after myocardial infarction: retrospective analysis in an outpatient population.

  2021cites this paper
• Ticagrelor: clinical development and future potential.

  2021cites this paper
• Antiagregacijska terapija prasugrelom i tikagrelorom u liječenju bolesnika s akutnim koronarnim sindromom Antiplatelet Therapy with Prasugrel and Ticagrelor in the Treatment of Patients with Acute Coronary Syndrome

  2021cites this paper
• P2Y12 blocker monotherapy after percutaneous coronary intervention

  2021cites this paper
• Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.

  2021cites this paper
• Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice

  2021cites this paper
• Short- and long-term cost-effectiveness of CYP2C19 genotype-guided therapy, universal clopidogrel, and universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.

  2021cites this paper
• Risk of infections in patients treated with ticagrelor versus clopidogrel: a systematic review and meta-analysis.

  2020cites this paper
• The risk of dyspnea in patients treated with third-generation P2Y12 inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials

  2020cites this paper
• OUTCOMES AND STRATEGY OF TAILORED ANTIPLATELET THERAPY WITH TICAGRELOR IN PATIENTS UNDERGOING TRANSCAROTID ARTERY REVASCULARIZATION (TCAR).

  2020cites this paper
• Sulfonic Acid Derivative-Modified SBA-15, PHTS and MCM-41 Mesoporous Silicas as Carriers for a New Antiplatelet Drug: Ticagrelor Adsorption and Release Studies

  2020cites this paper
• Recent Advances in the Role of the Adenosinergic System in Coronary Artery Disease.

  2020cites this paper
• Ticagrelor-Related Severe Dyspnoea: Mechanisms, Characteristic Features, Differential Diagnosis and Treatment

  2020cites this paper
• REAL-WORLD SAFETY AND EFFICACY OF TICAGRELOR IN PATIENTS WITH ST SEGMENT ELEVATION MYOCARDIAL INFARCTION AT ASSIUT UNIVERSITY HEART HOSPITAL

  2020cites this paper
• The Side Effects of TICAGRELOR among Saudi Patients and comparison with conventional anti-platelet drug clopidogrel at Aseer Central Hospital, Southwest of Saudi Arabia

  2020cites this paper
• The impact of CYP2C19 and CYP4F2 variants and clinical factors on treatment outcomes during antiplatelet therapy.

  2019cites this paper
• Invasive and antiplatelet treatment of patients with non‐ST‐segment elevation myocardial infarction: Understanding and addressing the global risk‐treatment paradox

  2019cites this paper
• Antithrombotic Agents: From Aspirin to DOACs in Coronary Artery Disease and in Atrial Fibrillation (Part I).

  2019cites this paper
• Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week.

  2019influential citation
• Ticagrelor-related late-onset dyspnea as cause of emergency department visit: a 3-year outpatient study

  2018cites this paper
• Successful Reversal of Bradycardia and Dyspnea With Aminophylline After Ticagrelor Load

  2018cites this paper
• Real-world incidence of patient-reported dyspnoea with ticagrelor

  2018cites this paper
• 2018 Expert Consensus on the Management of Adverse Effects of Antiplatelet Therapy for Acute Coronary Syndrome in Taiwan.

  2018cites this paper
• Coronary Artery Perforation Complicated by Pericardial Abscess Formation: A Clinical Dilemma

  2018cites this paper
• Ticagrelor safety profile in real-life setting of acute coronary syndrome patients.

  2017cites this paper
• Ticagrelor: Effects Beyond the P2Y12 Receptor.

  2017cites this paper
• Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals

  2017cites this paper
• Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction

  2017cites this paper
• Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease

  2017cites this paper
• Dyspnea in patients treated with P2Y12 receptor antagonists: insights from the GReek AntiPlatElet (GRAPE) registry

  2017cites this paper
• Dyspnea, with a focus on cardiovascular diseases: A primary health care perspective

  2016cites this paper
• Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations.

  2016cites this paper
• Dyspnea related to reversibly-binding P2Y12 inhibitors: A review of the pathophysiology, clinical presentation and diagnostics.

  2016cites this paper
• Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials

  2016cites this paper
• Comparative Efficacy and Safety of Prasugrel, Ticagrelor, and Standard-Dose and High-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis

  2016cites this paper
• Ticagrelor recommended over clopidogrel, only in clinical trials or also in a real-world practice?

  2016cites this paper
• Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients

  2016cites this paper
• Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?

  2016cites this paper
• Antiplatelet therapy - a summary for the general physicians.

  2016cites this paper
• Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients.

  2016cites this paper
• Ticagrelor‐induced dyspnoea

  2015cites this paper
• Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes

  2015cites this paper
• Practical experience with ticagrelor: an Australian and New Zealand perspective

  2015cites this paper
• Dyspnea in Post Percutaneous Transluminal Coronary Angioplasty (PTCA)Patients on Dual Antiplatelets in a Tertiary Care Hospital in South India

  2015cites this paper
• Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?

  2015cites this paper
• Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis

  2015cites this paper